EUVIMEDEUVIMED entdecken
Crossref

Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion–positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans

Katherine I Zhou iD, Vishal Vashistha iD, Aixia Guo, Sara Ahmed, Michael J Kelley iD

JCO Precision Oncology · 2023-03 · (7)

DOI: 10.1200/po.22.00692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023-03. Verfasst von Katherine I Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Durham VA Medical Center, Durham, NC. Hauptthemen laut MEDLINE: Neoplasms, Veterans. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Neurotrophic tyrosine receptor kinase 1-3 ( NTRK1-3) gene fusions are found in a broad range of tumor types. Clinical trials demonstrated high response rates to tropomyosin receptor kinase (TRK) inhibitors in NTRK fusion–positive cancers, but few reports have described real-world experience with these targeted agents. We evaluated the prevalence of NTRK fusions and the outcomes with TRK inhibitor therapy in a real-world population of patients in the Veterans Health Administration. METHODS Patients with NTRK fusions or rearrangements were identified from the Veterans Affairs (VA) National Precision Oncology Program (NPOP), and patients who were prescribed TRK inhibitors were identified from the Corporate Data Warehouse. Baseline data and clinical outcomes were obtained by retrospective review of medical records. RESULTS A total of 33 patients with NTRK fusions or rearrangements were identified, including 25 patients comprising 0.12% of all patients with solid tumors sequenced through VA NPOP. Twelve patients with NTRK fusions or rearrangements were treated with TRK inhibitors, none of whom had objective responses. Eight patients experienced toxicities leading to drug interruption, dose reduction, or discontinuation. CONCLUSION In this retrospective study of VA patients, NTRK fusions and rearrangements were less common than in previous studies, and objective responses to TRK inhibitors were not observed. Real-world experience with TRK inhibitors differs markedly from clinical trial findings, possibly due to differences in patient demographics, tumor types, and sequencing methods. Our findings highlight the need to study TRK inhibitors in the real-world setting and in populations underrepresented in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsVeteransHumansTropomyosinReceptor, trkARetrospective StudiesPrecision MedicineReceptors, Amino Acid

Substanzen

TropomyosinReceptor, trkAtyrosine receptorReceptors, Amino Acid

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Durham VA Medical Center, Durham, NC.
  • Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC.
  • Section of Hematology-Oncology, New Mexico VA Medical Center, Albuquerque, NM.
  • National Oncology Program, Department of Veterans Affairs, Durham, NC.

ORCID-Profile: Katherine I Zhou, Vishal Vashistha, Michael J Kelley

Zitieren

APA

Zhou, K. I., Vashistha, V., Guo, A., Ahmed, S., & Kelley, M. J. (2023). Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion–positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans. JCO Precision Oncology. https://doi.org/10.1200/po.22.00692

Vancouver

Zhou KI, Vashistha V, Guo A, Ahmed S, Kelley MJ. Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion–positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans. JCO Precision Oncology. 2023. doi:10.1200/po.22.00692

BibTeX
@article{Zhou2023,
  author = {Zhou, Katherine I and Vashistha, Vishal and Guo, Aixia and Ahmed, Sara and Kelley, Michael J},
  title = {Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion–positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans},
  journal = {JCO Precision Oncology},
  year = {2023},
  number = {7},
  doi = {10.1200/po.22.00692}
}
Kostenlos starten →